Pluri (NASDAQ:PLUR) Stock: Insider Alexandre Weinstein Manieu Acquires 833,334 Shares

Pluri Inc. (NASDAQ:PLUR) Director Alexandre Weinstein Manieu acquired 833,334 shares of the company’s stock in a transaction on Friday, October 23rd. The shares were purchased at an average cost of $1.50 per share, for a total transaction of $1,250,001.00. Following the acquisition, the director owned 2,083,334 shares of the company’s stock, valued at approximately $3,125,001. The trade was a 66.67% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Pluri Trading Up 13.1%

Shares of PLUR opened at $1.12 on Tuesday. The company’s 50 day simple moving average is $1.20 and its 200-day simple moving average is $2.42. The firm has a market cap of $14.12 million, a PE ratio of -0.46 and a beta of 0.69. Pluri Inc. has a 12-month low of $0.85 and a 12-month high of $4.87.

Pluri (NASDAQ:PLUR) last released its quarterly earnings results on Thursday, September 10th. The company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.66) by $0.12. The business had revenue of $0.34 million during the quarter, compared to analysts’ expectations of $0.66 million.

Analysts Set New Price Targets

Separately, Weiss Ratings downgraded shares of Pluri from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, August 26th. One research analyst has rated the stock with a Sell rating. According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Pluri Company Profile

Pluri Inc is a biotechnology company developing cell-based products and technologies for applications in human health, food production and other industries. The company’s platform uses three-dimensional cell expansion technology designed to grow cells at commercial scale without genetic modification.

Pluri’s health-related research has historically focused on placenta-derived, off-the-shelf cell therapies, including its PLX product candidates, which have been investigated for potential use in conditions involving inflammation, tissue damage and impaired blood flow.